Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Co.'s programs include: Levosimendan, which is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib (marketed in the U.S. as Gleevec®), which is a tyrosine kinase inhibitor. The TENX stock yearly return is shown above.
The yearly return on the TENX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TENX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|